Bioasis' latest feature in @BNNBloomberg discusses our recent partnerships with Janssen Biotech & Neuramedy Co., as well as the acquisition of EGF platform assets from the founders of Cresence AS, which paved the way for us to become a clinical-stage company. Read the article👇

The 2023 BIO International Convention is back to stand up for science! Bioasis (represented by John Proffett of Shadow Lake Group) will be meeting with potential partners 🤝 🗓️ June 5-8, 2023 | Boston Convention & Exhibition Center Learn more: bio.org/events/bio-internati…

Curious about how Bioasis Technologies is breaking through the blood-brain barrier to develop innovative therapies for neurological diseases? 🎥 Check out our video to learn more about the xB3 platform

At Bioasis Technologies, we believe everyone deserves access to life-changing therapies for challenging neurological diseases. That's why our team is leveraging our xB3 platform to develop novel therapies that can cross the blood-brain barrier & provide hope to patients in need.

🗓 May is #BrainTumorAwarenessMonth, and it's an important time to show support for all those affected by brain cancers. Let's use this month to raise awareness, educate others, and show compassion for those living with brain cancer.

🗓️ May is #MSAwarenessMonth and Bioasis is committed to improving the lives of those affected by Multiple Sclerosis through innovative treatments like CRES101 for optic neuritis associated with MS.

With 1.25 billion people worldwide affected by neurological diseases, the need for effective treatments has never been greater 🧠 We're dedicated to delivering innovative solutions that make a difference in the lives of patients. Find out more: bit.ly/313Wk9L

Studies have highlighted the role of mutations in the GBA gene as a genetic risk factor for Parkinson's disease. Our proprietary xB3 platform shows potential as a delivery method for therapeutics targeting the GBA gene & its related pathways. Details: bit.ly/3GEDIir

Myelin loss in neuroinflammatory diseases causes morbidity & lacks effective treatment Bioasis' acquired EGF assets stimulate oligodendrocyte & Schwann cell production - essential myelin-producing cells. Learn more about our groundbreaking research: bit.ly/39ZGL7I

Our proprietary xB3 platform enables the delivery of therapeutics into the brain 💊 🧠 It transports molecules across the blood-brain barrier & into the brain, where they can effectively treat neurological disorders. Learn more: bit.ly/3nuTpP1

At Bioasis, we're dedicated to developing innovative therapies to treat rare and difficult-to-treat brain disorders. Learn more about rare diseases 👉 bit.ly/3Zrs7e9

Bioasis has provided a business update. Read the full press release 👉 bit.ly/3z1Mjrj

Bioasis is exploring strategic alternatives to enhance shareholder value, including partnerships, financing alternatives & remaining a standalone company. Check out our website to learn about our ongoing efforts to drive value for our shareholders👇 bit.ly/3DvQmvF

Exciting news! Bioasis will be attending Bio-Europe Spring, one of the largest #biotechnology events in Europe. This event brings together leading minds in the industry to share insights and forge new partnerships. We can't wait to connect - learn more👇 bit.ly/3Lddzuc

It's Brain Awareness Week 🧠 We're dedicated to advancing brain health & developing therapies to treat neurological disorders. We support this important initiative & encourage everyone to get involved in raising awareness about brain health. Details: bit.ly/3ladfBJ

Today on #InternationalWomensDay, we celebrate the achievements of women in science globally. At Bioasis, we're proud to recognize the contributions of women in science, who continue to break barriers & pave the way for new discoveries. #IWD2023 Learn more👇

We've highlighted 3 indications that will be prioritized for development of CRES101: ✅ Guillain-Barré Syndrome ✅ Optic Neuritis associated with MS ✅ Chronic Inflammatory Demyelinating Polyneuritis Details: bit.ly/39ZGL7I

It's #RareDiseaseDay, a day to raise awareness about the challenges faced by people living with rare diseases. At Bioasis, we're committed to developing treatments for rare brain diseases that affect millions of people worldwide. Learn more👇 bit.ly/3lSSqL8

As we approach #RareDiseaseDay, we're reminded of the need for innovative treatments for these often-neglected conditions. At Bioasis, we're proud to be working towards that goal by developing cutting-edge therapies for rare brain disorders. Details👇 rarediseaseday.org/

Millions of people around the world are affected by neurodegenerative diseases. 🌎 Developing effective treatments for these diseases remains a critical challenge. Learn how our in-house development programs are designed to address this challenge: bit.ly/3JLCtNt

Bioasis is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting and is updating shareholders on its current financial condition. Get the details👇 bit.ly/3HTmhMa